- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04804605
Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-OLE)
November 29, 2023 updated by: Arcutis Biotherapeutics, Inc.
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects With Atopic Dermatitis
This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 52 weeks by subjects with atopic dermatitis (eczema).
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This is an open-label study in which ARQ-151 cream is applied once daily x 52 weeks to subjects with atopic dermatitis (eczema).
Study Type
Interventional
Enrollment (Actual)
1220
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Arcutis Medical Information
- Phone Number: 1-844-692-6729
- Email: medinfo@arcutis.com
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2J 7E1
- Arcutis Clinical Site 70
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3R 6A7
- Arcutis Clinical Site 27
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3M 3Z4
- Arcutis Clinical Site 55
-
-
New Brunswick
-
Fredericton, New Brunswick, Canada, E3B 1G9
- Arcutis Clinical Site 50
-
-
Ontario
-
Ajax, Ontario, Canada, L1S 7K8
- Arcutis Clinical Site 43
-
London, Ontario, Canada, N6H 5L5
- Arcutis Clinical Site 52
-
Markham, Ontario, Canada, L3P 1X3
- Clinical site 11
-
Mississauga, Ontario, Canada, L5H 1G9
- Clinical Site 46
-
Montréal, Ontario, Canada, H2X 2V1
- Arcutis Clinical Site 46
-
Peterborough, Ontario, Canada, K9J 5K2
- Arcutis Clinical Site 61
-
Toronto, Ontario, Canada, M4W 2N4
- Arcutis Clinical Site 54
-
Waterloo, Ontario, Canada, N2J 1C4
- Arcutis Clinical Site 39
-
Windsor, Ontario, Canada, N8W 1E6
- Clinical Site 09
-
-
Quebec
-
Drummondville, Quebec, Canada, J2B 5L4
- Arcutis Clinical Site 26
-
Montréal, Quebec, Canada, H2X 2V1
- Arcutis Clinical Site 45
-
Montréal, Quebec, Canada, H3Z 2S6
- Arcutis Clinical Site 56
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- Arcutis Clinical Site 112
-
Birmingham, Alabama, United States, 35244
- Arcutis Clinical Site 73
-
-
Arizona
-
Scottsdale, Arizona, United States, 85255
- Arcutis Clinical Site 63
-
-
Arkansas
-
Bryant, Arkansas, United States, 72022
- Arcutis Clinical Site 106
-
Fort Smith, Arkansas, United States, 72916
- Arcutis Clinical Site 116
-
-
California
-
Beverly Hills, California, United States, 90212
- Arcutis Clinical Site 69
-
Inglewood, California, United States, 90301
- Arcutis Clinical Site 81
-
San Francisco, California, United States, 94132
- Clinical Site 08
-
Santa Monica, California, United States, 90404
- Arcutis Clinical Site 31
-
Thousand Oaks, California, United States, 91320
- Arcutis Clinical Site 130
-
-
Colorado
-
Centennial, Colorado, United States, 80112
- Arcutis Clinical Site 123
-
-
Florida
-
Coral Gables, Florida, United States, 33134
- Arcutis Clinical Site 59
-
Coral Gables, Florida, United States, 33146
- Arcutis Clinical Site 72
-
Delray Beach, Florida, United States, 33484
- Arcutis Clinical Site 79
-
Hollywood, Florida, United States, 33021
- Arcutis Clinical Site 103
-
Jacksonville, Florida, United States, 32256
- Clinical Site 04
-
Largo, Florida, United States, 33770
- Arcutis Clinical Site 15
-
Miami, Florida, United States, 33162
- Arcutis Clinical Site 67
-
Miami, Florida, United States, 33173
- Arcutis Clinical Site 95
-
Miami, Florida, United States, 33174
- Arcutis Clinical Site 68
-
Sanford, Florida, United States, 32771
- Arcutis Clinical Site 29
-
Tampa, Florida, United States, 33613
- Clinical site 01
-
Wellington, Florida, United States, 33449
- Arcutis Clinical Site 138
-
-
Georgia
-
Sandy Springs, Georgia, United States, 30328
- Arcutis Clinical Site 47
-
-
Idaho
-
Boise, Idaho, United States, 83706
- Arcutis Clinical Site 145
-
-
Illinois
-
Rolling Meadows, Illinois, United States, 33770
- Arcutis Clinical Site 13
-
-
Indiana
-
Clarksville, Indiana, United States, 47129
- Arcutis Clinical Site 93
-
Plainfield, Indiana, United States, 46168
- Clinical Site 22
-
West Lafayette, Indiana, United States, 47906
- Arcutis Clinical Site 114
-
-
Kentucky
-
Louisville, Kentucky, United States, 40217
- Clinical Site 03
-
-
Louisiana
-
Covington, Louisiana, United States, 70433
- Arcutis Clinical Site 80
-
Lake Charles, Louisiana, United States, 70605
- Arcutis Clinical Site 85
-
Metairie, Louisiana, United States, 70006
- Arcutis Clinical Site 24
-
-
Maryland
-
Rockville, Maryland, United States, 20850
- Arcutis Clinical Site 76
-
-
Michigan
-
Bay City, Michigan, United States, 48706
- Arcutis Clinical Site 94
-
Clarkston, Michigan, United States, 48346
- Arcutis Clinical Site 88
-
Clinton Township, Michigan, United States, 48038
- Arcutis Clinical Site 58
-
Detroit, Michigan, United States, 48202
- Arcutis Clinical Site 66
-
Troy, Michigan, United States, 48084
- Arcutis Clinical Site 132
-
-
Minnesota
-
New Brighton, Minnesota, United States, 55112
- Clinical Site 10
-
-
Missouri
-
Saint Joseph, Missouri, United States, 64506
- Arcutis Clinical Site 102
-
-
Nevada
-
Reno, Nevada, United States, 89509
- Arcutis Clinical Site 62
-
-
New Jersey
-
East Windsor, New Jersey, United States, 08520
- Arcutis Clinical Site 71
-
-
New York
-
Kew Gardens, New York, United States, 11415
- Arcutis Clinical Site 96
-
Rochester, New York, United States, 14623
- Arcutis Clinical Site 82
-
-
North Carolina
-
High Point, North Carolina, United States, 27262
- Arcutis Clinical Site 19
-
-
Oregon
-
Gresham, Oregon, United States, 97030
- Arcutis Clinical Site 17
-
Portland, Oregon, United States, 97223
- Arcutis Clinical Site 16
-
Portland, Oregon, United States, 97239
- Arcutis Clinical Site 14
-
Portland, Oregon, United States, 97210
- Arcutis Clinical Site 108
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Arcutis Clinical Site 53
-
Newtown Square, Pennsylvania, United States, 19073
- Arcutis Clinical Site 64
-
Pittsburgh, Pennsylvania, United States, 15213
- Arcutis Clinical Site 25
-
-
Rhode Island
-
Johnston, Rhode Island, United States, 02919
- Arcutis Clinical Site 101
-
-
South Carolina
-
Charleston, South Carolina, United States, 29407
- Arcutis Clinical Site 77
-
Charleston, South Carolina, United States, 29425
- Arcutis Clinical Site 41
-
North Charleston, South Carolina, United States, 29420
- Clinical Site 33
-
Summerville, South Carolina, United States, 29486
- Arcutis Clinical Site 91
-
-
Tennessee
-
Murfreesboro, Tennessee, United States, 37130
- Arcutis Clinical Site 60
-
-
Texas
-
Arlington, Texas, United States, 76011
- Arcutis Clinical Site 34
-
Austin, Texas, United States, 78759
- Clinical Site 23
-
Bellaire, Texas, United States, 77401
- Arcutis Clinical Site 84
-
College Station, Texas, United States, 77845
- Arcutis Clinical Site 21
-
Frisco, Texas, United States, 75034
- Arcutis Clinical Site 126
-
Grapevine, Texas, United States, 76051
- Arcutis Clinical Site 118
-
Houston, Texas, United States, 77030
- Arcutis Clinical Site 48
-
Houston, Texas, United States, 77056
- Arcutis Clinical Site 35
-
Katy, Texas, United States, 77494
- Arcutis Clinical Site 109
-
San Antonio, Texas, United States, 78213
- Clinical Site 20
-
San Antonio, Texas, United States, 78218
- Arcutis Clinical Site 49
-
-
Utah
-
Orem, Utah, United States, 84058
- Arcutis Clinical Site 74
-
West Jordan, Utah, United States, 84088
- Arcutis Clinical Site 36
-
-
Virginia
-
Burke, Virginia, United States, 22015
- Arcutis Clinical Site 51
-
Norfolk, Virginia, United States, 23502
- Arcutis Clinical Site 40
-
-
Washington
-
Spokane, Washington, United States, 99202
- Arcutis Clinical Site 12
-
-
Wisconsin
-
Kenosha, Wisconsin, United States, 53142
- Arcutis Clinical Site 133
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- For adult subjects: Participants legally competent to sign and give informed consent. For pediatric and adolescent subjects: Informed consent of parent(s) or legal guardian, and, if age appropriate, assent by the subjects, as required by local laws.
- Males and females, ages 2 years and older. (Only subjects 18 years and older will be enrolled at sites located in the province of Québec in Canada.)
- Subjects with atopic dermatitis who met eligibility criteria for and successfully completed one of three preceding studies through Week 4, and are able and eligible to enroll into this long-term safety study on the Week 4 visit of the preceding study.
- Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at all study visits. In addition, sexually active FOCBP must agree to use at least one form of a highly effective or barrier method of contraception throughout the trial.
- Females of non-childbearing potential should either be pre-menarchal, or post-menopausal with spontaneous amenorrhea for at least 12 months (post-menopausal status would have been confirmed with FSH testing in the preceding study) or have undergone surgical sterilization (permanent sterilization methods include hysterectomy, bilateral oophorectomy, or bilateral salpingectomy).
- Subjects and parent(s)/legal guardian(s) are considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.
Exclusion Criteria:
- Subjects who experienced a treatment-related AE or a serious AE (SAE) that precluded further treatment with ARQ-151 cream in the preceding study.
- Subjects that use any Excluded Medications and Treatments.
- Subjects with skin conditions other than AD that would interfere with evaluations of the effect of the study medication on AD, as determined by the Investigator. Subjects with any condition on the treatment area which, in the opinion of the Investigator, could confound efficacy measurements.
- Subjects with known genetic dermatological conditions that overlap with AD.
- Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
- Subjects and parent(s)/legal guardian(s) who are unable to communicate, read or understand the local language(s), or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.
- Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members of enrolled subjects (subjects enrolled in other studies of ARQ-151 cream) living in the same house.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
|
ARQ-151 Cream
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess long-term safety in a multicenter, open-label, single-arm, 52-week study in subjects with atopic dermatitis treated with ARQ-151 cream: AEs and SAEs
Time Frame: 24 or 52 weeks
|
AEs and SAEs
|
24 or 52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) score of 0 or 1 at each assessment
Time Frame: 24 or 52 weeks
|
The vIGA-AD is a static evaluation of qualitative overall AD severity.
This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).
|
24 or 52 weeks
|
vIGA-AD success
Time Frame: 24 or 52 weeks
|
Defined as vIGA-AD value of 0 or 1 plus a 2-grade improvement from baseline
|
24 or 52 weeks
|
WI-NRS score over time
Time Frame: 24 or 52 weeks
|
WI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period.
The scale is from '0 to 10' ("no itch" to "worst imaginable itch").
|
24 or 52 weeks
|
EASI score over time
Time Frame: 24 or 52 weeks
|
EASI combines the assessment of the severity of lesions and the area affected into a single total score in the range 0 (no disease) to 72 (maximal disease).
To calculate the EASI, the sum of the severity rating (0 to 3 with 3 being the most severe) for four clinical signs are multiplied with the numerical value of the area affected and with the percentage of the four body areas.
|
24 or 52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: David Berk, MD, Arcutis Biotherapeutics, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 25, 2021
Primary Completion (Estimated)
May 31, 2024
Study Completion (Estimated)
May 31, 2024
Study Registration Dates
First Submitted
March 16, 2021
First Submitted That Met QC Criteria
March 17, 2021
First Posted (Actual)
March 18, 2021
Study Record Updates
Last Update Posted (Estimated)
December 1, 2023
Last Update Submitted That Met QC Criteria
November 29, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ARQ-151-313
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis Eczema
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
University of California, DavisCompletedAtopic Dermatitis | Hand Eczema | Atopic Eczema | Infantile EczemaUnited States
-
Kari NadeauKing's College London; National Institute of Allergy and Infectious Diseases... and other collaboratorsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Eczema, InfantileUnited States, United Kingdom
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Petra LarmoCliniscan LtdTerminated
-
Groningen Research Institute for Asthma and COPDNumico Research Wageningen, the NetherlandsCompletedAtopic Dermatitis | Atopic Eczema | Infantile EczemaNetherlands
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
ShaperonNot yet recruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of Scalp
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
University College CorkCompletedEczema | Food Allergy | Eczema, Infantile | Eczema Atopic DermatitisIreland
Clinical Trials on ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
-
Arcutis Biotherapeutics, Inc.CompletedAtopic Dermatitis (Eczema)United States
-
Arcutis Biotherapeutics, Inc.CompletedPsoriasisCanada, United States
-
Arcutis Biotherapeutics, Inc.CompletedAtopic DermatitisUnited States, Canada
-
Arcutis Biotherapeutics, Inc.CompletedChronic Plaque PsoriasisUnited States, Canada
-
Arcutis Biotherapeutics, Inc.CompletedPlaque PsoriasisUnited States
-
Arcutis Biotherapeutics, Inc.CompletedChronic Plaque PsoriasisUnited States, Canada
-
Arcutis Biotherapeutics, Inc.CompletedMaximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)Psoriasis | Plaque PsoriasisUnited States, Canada, Dominican Republic
-
Arcutis Biotherapeutics, Inc.CompletedAtopic Dermatitis EczemaUnited States, Canada
-
Arcutis Biotherapeutics, Inc.CompletedChronic Plaque PsoriasisUnited States, Canada, Dominican Republic
-
Arcutis Biotherapeutics, Inc.CompletedMaximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)Psoriasis | Plaque PsoriasisUnited States, Canada, Dominican Republic